JP2023088902A5 - - Google Patents

Download PDF

Info

Publication number
JP2023088902A5
JP2023088902A5 JP2023020149A JP2023020149A JP2023088902A5 JP 2023088902 A5 JP2023088902 A5 JP 2023088902A5 JP 2023020149 A JP2023020149 A JP 2023020149A JP 2023020149 A JP2023020149 A JP 2023020149A JP 2023088902 A5 JP2023088902 A5 JP 2023088902A5
Authority
JP
Japan
Prior art keywords
raav
promoter
seq
cep290
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023020149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023088902A (ja
JP7535332B2 (ja
Filing date
Publication date
Priority claimed from JP2019555010A external-priority patent/JP7307480B2/ja
Application filed filed Critical
Publication of JP2023088902A publication Critical patent/JP2023088902A/ja
Publication of JP2023088902A5 publication Critical patent/JP2023088902A5/ja
Application granted granted Critical
Publication of JP7535332B2 publication Critical patent/JP7535332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023020149A 2017-04-05 2023-02-13 ミニ遺伝子療法 Active JP7535332B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762481727P 2017-04-05 2017-04-05
US62/481,727 2017-04-05
JP2019555010A JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法
PCT/US2018/026230 WO2018187552A1 (en) 2017-04-05 2018-04-05 Minigene therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019555010A Division JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法

Publications (3)

Publication Number Publication Date
JP2023088902A JP2023088902A (ja) 2023-06-27
JP2023088902A5 true JP2023088902A5 (enExample) 2023-10-31
JP7535332B2 JP7535332B2 (ja) 2024-08-16

Family

ID=63712901

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555010A Active JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法
JP2023020149A Active JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019555010A Active JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法

Country Status (7)

Country Link
US (3) US11739346B2 (enExample)
EP (1) EP3606544B1 (enExample)
JP (2) JP7307480B2 (enExample)
CN (2) CN118360335A (enExample)
AU (2) AU2018248304C1 (enExample)
CA (1) CA3059112A1 (enExample)
WO (1) WO2018187552A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6993970B2 (ja) * 2015-11-16 2022-02-15 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を低減させるように操作された細菌
EP3606544B1 (en) 2017-04-05 2025-06-04 University of Massachusetts Minigene therapy
EP3956453A4 (en) 2019-04-19 2023-02-22 University of Massachusetts GENE THERAPIES FOR USHER SYNDROME (USH1B)
US20220202959A1 (en) * 2019-04-19 2022-06-30 University Of Massachusetts Gene therapies for usher syndrome (ush2a)
US12390539B2 (en) 2019-05-20 2025-08-19 University Of Massachusetts Minigene therapy
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
CN112062827B (zh) * 2020-09-16 2022-10-21 中国人民解放军军事科学院军事医学研究院 Cep55蛋白在调控纤毛去组装和制备纤毛相关疾病模型中的应用
EP4255457A4 (en) * 2020-12-03 2025-05-21 University of Massachusetts DEVELOPMENT OF NEW GENE THERAPEUTIC AGENTS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
WO2022169774A1 (en) * 2021-02-02 2022-08-11 University Of Massachusetts Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
AU2009231171A1 (en) 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US10266845B2 (en) 2013-02-08 2019-04-23 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
US10155794B2 (en) 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
CN105980569A (zh) * 2013-08-05 2016-09-28 莱顿大学医学中心附属莱顿教学医院 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
EP3185909B1 (en) 2014-08-27 2024-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods and compositions for treating leber congenital amaurosis
AU2016355343C1 (en) 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
EP3393522B1 (en) 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
US20170348387A1 (en) * 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
EP3606544B1 (en) 2017-04-05 2025-06-04 University of Massachusetts Minigene therapy
KR20250023600A (ko) 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
KR102763312B1 (ko) 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
US12390539B2 (en) 2019-05-20 2025-08-19 University Of Massachusetts Minigene therapy

Similar Documents

Publication Publication Date Title
JP2023535956A5 (enExample)
CN106459932B (zh) 高胆红素血症的治疗
JP2020512822A5 (enExample)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2022523679A5 (enExample)
JP2023515072A5 (enExample)
JP2022529782A5 (enExample)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
US20190309326A1 (en) Dual overlapping adeno-associated viral vector system for expressing abca4
JP2022501060A5 (enExample)
JP2022547197A5 (enExample)
JP2023535576A5 (enExample)
JP2021533805A5 (enExample)
JP2022525302A5 (enExample)
JP2021500922A5 (enExample)
JP2017529395A5 (enExample)
CN121575014A (zh) 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗
JP2024546103A5 (enExample)
JP2022539156A (ja) ヒアルロン酸を用いた眼組織へのaav媒介形質導入の増強
AU2023406927A1 (en) Adeno-associated viral vectors for proper packaging of repetitive elements
JP2023522883A (ja) 神経学的障害を処置するための組成物および方法
US20220389450A1 (en) Vector system
EP4601708A1 (en) Bdnf gene therapy
CN121127272A (zh) 用于治疗眼底黄色斑点症的双aav载体
CN120400250A (zh) 表达myo7a蛋白的双载体系统及其用途